Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Apr 8, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, compliance
TL;DR
Genmab filed a routine 6-K, no new info, just housekeeping.
AI Summary
Genmab A/S filed a Form 6-K on April 8, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial data but serves as an update for its ongoing reporting requirements as a foreign private issuer.
Why It Matters
This filing is primarily a procedural update for SEC registration, indicating ongoing compliance rather than new business developments.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not contain new material information that would typically impact risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 001-38976 (dollar_amount) — SEC File Number
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
What is Genmab A/S's SEC file number?
Genmab A/S's SEC file number is 001-38976.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 8, 2024.
Does this report contain new annual financial information?
No, this report is filed for the month of April 2024 and is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16, not an annual report.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive office is located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-04-08 13:41:38
Filing Documents
- tmb-20240408x6k.htm (6-K) — 19KB
- tmb-20240408xex99d1.htm (EX-99.1) — 61KB
- tmb-20240408xex99d1a.htm (EX-99.1(A)) — 5711KB
- tmb-20240408xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240408xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-004816.txt ( ) — 5805KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: April 8, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 8, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix: Share Buy-Back Program Transactions April 1 to 5, 2024